Table 3 The association between high- and low- immune risk score and OS of LUAD patients in training, validation dataset-1 and validation dataset-2
From: An individualized immune prognostic signature in lung adenocarcinoma
Training dataset (N = 520) | Validation dataset-1 (N = 436) | Validation dataset-2 (N = 381) | |||||||
|---|---|---|---|---|---|---|---|---|---|
(High/low) | HR (95% CI) | p value | (High/low) | HR (95% CI) | p value | (High/low) | HR (95% CI) | p value | |
Total | 215/305 | 2.77 (2.08–3.67) | < 0.01 | 183/253 | 1.56 (1.20–2.02) | < 0.01 | 109/272 | 1.83 (1.24–2.78) | < 0.01 |
Age | |||||||||
< 70 | 165/236 | 2.97 (2.09–4.24) | < 0.01 | 119/171 | 1.53 (1.11–2.13) | 0.01 | 56/119 | 1.93 (1.06–3.52) | 0.03 |
≥ 70 | 50/69 | 2.87 (1.76–4.69) | < 0.01 | 64/82 | 1.71 (1.12–2.63) | 0.05 | 53/153 | 1.82 (1.08–3.05) | 0.02 |
Gender | |||||||||
Male | 132/139 | 2.28 (1.57–3.31) | < 0.01 | 102/116 | 1.42 (1.01–2.00) | 0.04 | 54/114 | 1.95 (1.14–3.33) | < 0.01 |
Female | 83/166 | 3.47 (2.23–5.39) | < 0.01 | 81/176 | 1.66 (1.11–2.47) | 0.01 | 55/158 | 1.66 (0.93–2.95) | 0.09 |
Stage | |||||||||
I/II | 205/297 | 2.73 (2.03–3.65) | < 0.01 | 150/218 | 1.66 (1.23–2.25) | < 0.01 | 85/226 | 2.06 (1.29–3.29) | < 0.01 |
III/IV | 10/8 | 2.71 (0.83–8.87) | 0.10 | 35/33 | 0.95 (0.57–1.59) | 0.85 | 24/46 | 1.20 (0.59–2.47) | 0.61 |
Purity | |||||||||
< 0.5 | 146/174 | 3.33 (2.30–4.82) | < 0.01 | 52/61 | 1.95 (1.11–3.41) | 0.02 | 42/84 | 1.70 (0.89–3.24) | 0.11 |
≥ 0.5 | 69/131 | 2.11 (1.33–3.33) | 0.01 | 131/192 | 1.50 (1.11–2.02) | < 0.01 | 67/188 | 1.93 (1.17–3.13) | < 0.01 |